title: Low density lipoproteins inhibit endotoxin activation of monocytes.
abstract: Human serum and low density lipoproteins (LDLs) were shown to inactivate endotoxin (lipopolysaccharide [LPS]) by testing the effect of LPS interactions with serum or LDL on the activation of human monocytes. Sera and LDL preparations from four patients with familial hypercholesterolemia were used to demonstrate the inhibition of LPS from inducing interleukin-1 release. Before LDL removal by immunoapheresis, the patients' sera were able to inactive approximately fivefold more LPS than after LDL removal. The LPS-inactivating capacity lost during apheresis could essentially be retrieved in the LDL-rich eluate from the immunoadsorption columns. Because patients were treated frequently with immunoapheresis, their LDL levels before LDL removal were not markedly elevated. These patients' sera before LDL removal were shown to inactivate amounts of LPS comparable to those inactivated by the sera from three healthy volunteers. LDL prepared by ultracentrifugation showed similar LPS inactivation as LDL prepared by immunoapheresis. We conclude that the inhibition of LPS-induced monocyte activation by human serum is dependent to a large extent on the LDL fraction. LDLs were demonstrated to inhibit LPS from inducing interleukin-1 release by human monocytes.
authors.affiliation: Department of Transfusion Medicine, University of Ulm, German Red Cross Blood Center.
authors.forename: C
authors.initials: C
authors.lastname: Weinstock
authors.forename: H
authors.initials: H
authors.lastname: Ullrich
authors.forename: R
authors.initials: R
authors.lastname: Hohe
authors.forename: A
authors.initials: A
authors.lastname: Berg
authors.forename: M W
authors.initials: MW
authors.lastname: Baumstark
authors.forename: I
authors.initials: I
authors.lastname: Frey
authors.forename: H
authors.initials: H
authors.lastname: Northoff
authors.forename: W A
authors.initials: WA
authors.lastname: Flegel
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000276:immunology; D001781:Blood Component Removal; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood; D007106:Immune Sera; D007163:Immunosorbent Techniques; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000502:physiology*; D014461:Ultracentrifugation
chemical_list: D001055:Apolipoproteins B; D007106:Immune Sera; D008070:Lipopolysaccharides; D008077:Lipoproteins, LDL